See more : Shouhang High-Tech Energy Co., Ltd. (002665.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Senstar Technologies Ltd. (SNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senstar Technologies Ltd., a leading company in the Security & Protection Services industry within the Industrials sector.
You may be interested
- Westhaven Gold Corp. (WTHVF) Income Statement Analysis – Financial Results
- Trucknet Enterprise Ltd (TRAN.TA) Income Statement Analysis – Financial Results
- Cyber Security 1 AB (publ) (CYBNY) Income Statement Analysis – Financial Results
- TDCX Inc. (TDCX) Income Statement Analysis – Financial Results
- AGI Infra Limited (AGIIL.BO) Income Statement Analysis – Financial Results
Senstar Technologies Ltd. (SNT)
Industry: Security & Protection Services
Sector: Industrials
Website: https://www.senstartechnologies.com
About Senstar Technologies Ltd.
Senstar Technologies Ltd. develops, manufactures, markets, and sells perimeter intrusion detection sensors, physical barriers, video analytics and management systems, and security video observation and surveillance systems. The company offers Perimeter Intrusion Detection Systems (PIDS), fence mounted, buried, and free standing; PIDS fence sensor with intelligent perimeter LED based lighting; common operating platform for video management software, including intelligent video analytics applications, PIDS, and electronic access control systems; security thermal imaging observation and surveillance systems; and life safety or duress alarm systems. The company's products are used to protect borders and sensitive facilities, including military bases, power plants, air and sea ports, prisons, industrial sites, large retailer organizations, banks, and oil and gas facilities; sporting events, including athlete villages and stadiums, and municipalities from intrusion, terror, crime, sabotage or vandalism to infrastructure, assets and personnel. Senstar Technologies Ltd. sells its products through system integrators and distribution channels. The company was formerly known as Magal Security Systems Ltd. and changed its name to Senstar Technologies Ltd. in September 2021. Senstar Technologies Ltd. was incorporated in 1984 and is based in Ramat Gan, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.79M | 35.56M | 34.92M | 81.27M | 86.83M | 92.60M | 64.29M | 67.83M | 63.74M | 77.54M | 51.52M | 77.70M | 88.59M | 49.70M | 54.52M | 70.36M | 72.38M | 66.96M | 61.28M | 60.97M | 59.36M | 42.97M | 41.02M | 38.57M | 31.97M | 32.10M | 25.50M | 18.20M | 17.10M | 16.80M | 10.70M |
| Cost of Revenue | 13.94M | 14.06M | 12.94M | 46.71M | 48.07M | 52.30M | 32.97M | 34.57M | 32.72M | 43.05M | 31.06M | 44.16M | 49.09M | 31.40M | 33.33M | 49.21M | 43.51M | 40.23M | 39.15M | 33.73M | 33.38M | 23.92M | 21.51M | 20.52M | 15.26M | 15.20M | 12.00M | 9.90M | 8.80M | 8.50M | 5.50M |
| Gross Profit | 18.85M | 21.50M | 21.98M | 34.56M | 38.76M | 40.30M | 31.33M | 33.26M | 31.01M | 34.49M | 20.46M | 33.53M | 39.50M | 18.30M | 21.19M | 21.15M | 28.87M | 26.73M | 22.13M | 27.25M | 25.98M | 19.04M | 19.52M | 18.05M | 16.70M | 16.90M | 13.50M | 8.30M | 8.30M | 8.30M | 5.20M |
| Gross Profit Ratio | 57.48% | 60.47% | 62.95% | 42.52% | 44.64% | 43.52% | 48.72% | 49.03% | 48.66% | 44.48% | 39.71% | 43.16% | 44.59% | 36.82% | 38.86% | 30.06% | 39.88% | 39.92% | 36.11% | 44.69% | 43.77% | 44.32% | 47.57% | 46.79% | 52.25% | 52.65% | 52.94% | 45.60% | 48.54% | 49.40% | 48.60% |
| Research & Development | 4.01M | 4.03M | 3.93M | 5.66M | 6.37M | 6.85M | 6.56M | 6.78M | 4.81M | 4.60M | 4.41M | 4.04M | 3.90M | 4.11M | 4.82M | 6.20M | 5.76M | 5.38M | 5.27M | 4.68M | 4.77M | 3.13M | 3.05M | 2.98M | 2.68M | 2.30M | 2.00M | 2.00M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 6.98M | 6.97M | 9.71M | 9.45M | 11.14M | 7.85M | 7.45M | 7.03M | 8.90M | 7.79M | 7.41M | 8.68M | 7.59M | 8.22M | 13.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.95M | 9.01M | 10.00M | 13.83M | 16.90M | 18.56M | 18.16M | 17.54M | 14.79M | 17.13M | 12.78M | 16.53M | 19.42M | 11.26M | 10.88M | 17.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.11M | 15.99M | 16.97M | 23.54M | 26.35M | 29.70M | 26.01M | 24.98M | 21.81M | 26.03M | 20.57M | 23.94M | 28.10M | 18.85M | 19.09M | 30.65M | 20.40M | 18.61M | 19.14M | 18.45M | 16.89M | 13.58M | 12.88M | 11.79M | 9.92M | 10.40M | 8.20M | 4.20M | 6.30M | 5.70M | 3.70M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.11M | 20.02M | 20.90M | 29.20M | 32.72M | 36.55M | 32.57M | 31.76M | 26.63M | 30.63M | 24.98M | 27.98M | 29.69M | 22.96M | 23.91M | 36.84M | 26.10M | 23.99M | 24.41M | 24.33M | 21.66M | 16.71M | 15.94M | 14.77M | 14.03M | 14.10M | 12.30M | 6.80M | 6.90M | 6.30M | 4.20M |
| Cost & Expenses | 34.06M | 34.07M | 33.84M | 75.91M | 80.79M | 88.85M | 65.54M | 66.33M | 59.35M | 73.68M | 56.04M | 72.14M | 78.78M | 54.36M | 57.24M | 86.05M | 69.61M | 64.22M | 63.56M | 58.06M | 55.04M | 40.63M | 37.44M | 35.29M | 29.29M | 29.30M | 24.30M | 16.70M | 15.70M | 14.80M | 9.70M |
| Interest Income | 151.00K | 48.00K | 26.00K | 158.00K | 664.00K | 670.00K | 462.00K | 303.00K | 54.00K | 141.00K | 337.00K | 671.00K | 1.91M | 182.00K | 484.00K | 864.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 157.00K | 273.00K | 52.00K | 310.00K | 360.00K | 412.00K | 349.00K | 299.00K | 381.00K | 493.00K | 406.00K | 602.00K | 1.16M | 967.00K | 1.57M | 2.01M | 1.90M | 1.39M | 1.25M | 1.30M | 1.11M | 0.00 | 942.00K | 214.00K | 0.00 | 900.00K | 0.00 | 200.00K | 100.00K | 300.00K | 200.00K |
| Depreciation & Amortization | 917.00K | 1.43M | 1.87M | 1.96M | 2.10M | 2.25M | 1.88M | 1.74M | 1.50M | 1.97M | 1.72M | 1.18M | 1.22M | 1.06M | 1.20M | 3.06M | 2.14M | 2.21M | 2.40M | 2.15M | 1.40M | 1.11M | 1.43M | 1.38M | 1.43M | 1.40M | 2.10M | 600.00K | 600.00K | 600.00K | 500.00K |
| EBITDA | -255.00K | 3.06M | 1.94M | 3.99M | 6.47M | 7.36M | -2.98M | 2.94M | 6.92M | 5.86M | -2.34M | 6.87M | 12.94M | -3.62M | -2.26M | -13.59M | 4.91M | 4.94M | 125.00K | 5.22M | 5.68M | 3.45M | 5.01M | 4.67M | 4.10M | 4.20M | 3.31M | 2.10M | 2.00M | 2.60M | 1.50M |
| EBITDA Ratio | -0.78% | 4.17% | 3.10% | 6.59% | 6.95% | 4.05% | 1.70% | 2.20% | 6.89% | 8.13% | -8.77% | 7.15% | 14.61% | -9.38% | -4.99% | -17.95% | 8.79% | 8.34% | 0.62% | 10.21% | 10.60% | 8.02% | 12.22% | 12.10% | 14.57% | 13.08% | 20.39% | 11.54% | 11.70% | 15.48% | 14.02% |
| Operating Income | -1.27M | 54.00K | -788.00K | 3.40M | 3.94M | 3.76M | -1.24M | 1.50M | 4.39M | 1.42M | -4.52M | 5.56M | 9.81M | -4.66M | -2.72M | -28.58M | 2.77M | 2.74M | -2.28M | 2.92M | 4.32M | 2.33M | 3.58M | 3.28M | 2.67M | 2.80M | 1.20M | 1.50M | 1.40M | 2.00M | 1.00M |
| Operating Income Ratio | -3.86% | 0.15% | -2.26% | 4.18% | 4.54% | 4.05% | -1.93% | 2.20% | 6.89% | 1.84% | -8.77% | 7.15% | 11.07% | -9.38% | -4.99% | -40.62% | 3.83% | 4.09% | -3.72% | 4.78% | 7.28% | 5.43% | 8.73% | 8.51% | 8.36% | 8.72% | 4.71% | 8.24% | 8.19% | 11.90% | 9.35% |
| Total Other Income/Expenses | -64.00K | 141.00K | -1.01M | -1.02M | 3.78M | 1.36M | -3.96M | -591.00K | 642.00K | -595.00K | 59.00K | -472.00K | 756.00K | -967.00K | -1.57M | -16.03M | -2.20M | -851.00K | -800.00K | -762.00K | -1.00M | 199.00K | 40.00K | -214.00K | -484.00K | -205.00K | -1.91M | -200.00K | -100.00K | 0.00 | -200.00K |
| Income Before Tax | -1.33M | 1.63M | 70.00K | 3.90M | 4.37M | 5.12M | -5.21M | 904.00K | 5.03M | 3.40M | -4.46M | 5.09M | 10.57M | -5.63M | -4.29M | -30.59M | 569.00K | 1.89M | -3.06M | 2.15M | 3.32M | 2.53M | 3.62M | 3.07M | 2.19M | 2.60M | -700.00K | 1.30M | 1.30M | 0.00 | 800.00K |
| Income Before Tax Ratio | -4.05% | 4.57% | 0.20% | 4.80% | 5.04% | 5.52% | -8.10% | 1.33% | 7.89% | 4.39% | -8.66% | 6.54% | 11.93% | -11.32% | -7.87% | -43.48% | 0.79% | 2.82% | -4.99% | 3.53% | 5.59% | 5.90% | 8.82% | 7.96% | 6.85% | 8.10% | -2.75% | 7.14% | 7.60% | 0.00% | 7.48% |
| Income Tax Expense | -40.00K | -2.40M | 2.26M | 3.00M | 1.55M | 2.07M | 1.70M | -122.00K | 1.92M | 82.00K | 69.00K | 991.00K | 723.00K | 602.00K | 728.00K | 1.62M | 373.00K | 948.00K | -23.00K | 1.10M | 913.00K | 645.00K | 452.00K | 180.00K | 259.00K | 300.00K | 200.00K | 100.00K | 200.00K | 300.00K | 200.00K |
| Net Income | -1.29M | 3.83M | -2.19M | 902.00K | 2.29M | 2.95M | -6.91M | 1.03M | 3.14M | 3.41M | -4.46M | 4.09M | 9.84M | -6.21M | -855.00K | -32.60M | 1.88M | 810.00K | -3.21M | 1.05M | 2.40M | 1.89M | 3.17M | 2.89M | 1.93M | 2.30M | -900.00K | 1.20M | 1.10M | 1.70M | 600.00K |
| Net Income Ratio | -3.93% | 10.77% | -6.28% | 1.11% | 2.64% | 3.18% | -10.75% | 1.52% | 4.93% | 4.40% | -8.66% | 5.27% | 11.11% | -12.49% | -1.57% | -46.34% | 2.60% | 1.21% | -5.24% | 1.73% | 4.05% | 4.39% | 7.72% | 7.49% | 6.04% | 7.17% | -3.53% | 6.59% | 6.43% | 10.12% | 5.61% |
| EPS | -0.06 | 0.16 | -0.09 | 0.04 | 0.10 | 0.13 | -0.30 | 0.06 | 0.18 | 0.20 | -0.26 | 0.25 | 0.74 | -0.56 | -0.08 | -2.96 | 0.17 | 0.08 | -0.30 | 0.11 | 0.27 | 0.21 | 0.36 | 0.31 | 0.21 | 0.25 | -0.10 | 0.19 | 0.16 | 0.25 | 0.10 |
| EPS Diluted | -0.06 | 0.16 | -0.09 | 0.04 | 0.10 | 0.13 | -0.30 | 0.06 | 0.18 | 0.20 | -0.26 | 0.25 | 0.74 | -0.56 | -0.08 | -2.96 | 0.17 | 0.08 | -0.30 | 0.11 | 0.27 | 0.20 | 0.36 | 0.31 | 0.21 | 0.25 | -0.10 | 0.19 | 0.16 | 0.25 | 0.10 |
| Weighted Avg Shares Out | 21.48M | 23.31M | 23.21M | 23.15M | 23.13M | 23.04M | 22.99M | 18.00M | 17.29M | 17.12M | 17.07M | 16.92M | 13.37M | 11.02M | 11.02M | 11.02M | 11.08M | 10.73M | 10.63M | 9.30M | 8.92M | 9.02M | 8.69M | 9.25M | 9.18M | 9.18M | 8.84M | 6.39M | 6.69M | 6.70M | 6.19M |
| Weighted Avg Shares Out (Dil) | 23.31M | 23.31M | 23.21M | 23.15M | 23.14M | 23.29M | 22.99M | 18.03M | 17.35M | 17.28M | 17.07M | 16.95M | 13.37M | 11.02M | 11.02M | 11.02M | 11.08M | 10.73M | 10.63M | 9.30M | 8.92M | 9.25M | 8.90M | 9.25M | 9.27M | 9.18M | 8.84M | 6.39M | 6.69M | 6.70M | 6.19M |
Senesco to Present at NYSSA's 2011 Biotech / Specialty Pharma Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at NYSSA's 2011 Biotech / Specialty Pharma Conference being held at The Conference Facilities of The New York Society of Security...
Senesco Technologies Reports First Quarter Fiscal 2012 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today reported financial results for the first quarter of fiscal year 2012 which ended on September 30, 2011. Highlights of the first quarter and recent weeks include: Initiated...
Emerging Biotech Companies Discuss What’s in the Pipeline at NYSSA Conference
NEW YORK--(BUSINESS WIRE)--Insiders from some of the sector’s most innovative small- and micro-cap biotech companies will discuss their progress with trials and their plans to develop, research, and market important new drugs, diagnostics and delivery technologies at the New York...
Senesco Initiates Dosing in Phase 1b/2a Clinical Study of SNS01-T
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced the initiation of patient dosing in its Phase 1b/2a clinical study of SNS01-T at the Mayo Clinic in Rochester, MN. The study is an open-label, multiple-dose,...
Senesco Technologies Provides Corporate Update
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) provided an update on Company activities. Clinical Trial Status Update Senesco has its first clinical trial of SNS01-T open at the Mayo Clinic in Rochester, MN. The study...
Senesco Technologies Receives Notice of Non-Compliance from NYSE Amex
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (the “Company”) (NYSE Amex: SNT) has received a notice from the NYSE Amex LLC (the “NYSE Amex”) providing notification that the Company does not meet one of the NYSE Amex’s continued listing standards as...
Senesco Technologies to Present at BIO Investor Forum Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at the BIO Investor Forum conference on Tuesday, October 25th. Leslie J. Browne, Ph.D., President and CEO of Senesco will be...
Senesco Technologies Reports Fiscal Year 2011 Financial Results
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today announced financial results for the 12 months ended June 30, 2011 (“Fiscal 2011”). Fiscal Fourth Quarter and Recent Highlights Senesco’s lead therapeutic candidate, SNS01-T, was granted FDA...
Senesco to Present at 13th Annual Rodman & Renshaw Healthcare Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced that the Company will be presenting at the 13th Annual Rodman & Renshaw Healthcare Conference being held at the Waldorf Astoria in New York City from September...
Senesco Finalizes Agreement with Mayo Clinic to Study SNS01-T in Multiple Myeloma
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT) today announced that it has finalized a clinical trial agreement with Mayo Clinic in Rochester, MN to study SNS01-T, the Company’s lead therapeutic candidate for the treatment of...
Source: https://incomestatements.info
Category: Stock Reports